Pediatric uveitis is a serious disease that can cause permanent vision loss. Many children with noninfectious uveitis require treatment with tumor necrosis factor inhibitors (TNFi) to control uveitis and prevent complications. The most commonly used TNFi in childhood uveitis is adalimumab (ADA). Some children with uveitis respond to standard juvenile arthritis ADA dosing, while others require increased doses or do not achieve disease control on ADA. Therapeutic drug monitoring (TDM), a strategy of adjusting medication doses based on blood levels of the medication, is increasingly used in other diseases. TDM is not currently used in uveitis because target drug levels in uveitis are unknown. This project will enroll 85 children who are starting adalimumab for chronic anterior uveitis and measure ADA levels and antibodies several times in the first months of treatment. This pilot project is a first step towards defining optimal ADA trough levels in treatment of childhood uveitis.